EUCTR2006-005473-21-IT进行中（未招募）不适用
An open label extension study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension. - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients who qualified and entered core study CVAL489K2303. 2. Patients who participated in the core study CVAL489K2303, completed period 1 and were re-randomized in period 2 and continued for at least 3 days in period 2.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients who did not complete period 1 of the core study. 2. Patients who were re-randomized in period 2 of core study but did not continue for >=3 days in period 2 of the core study.
研究者
相似试验
进行中（未招募）
1 期
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 6 months -5 years old with hypertension.HypertensionEUCTR2006-005473-21-BEovartis Pharma Services AG66
进行中（未招募）
不适用
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionEUCTR2006-005473-21-HUovartis Pharma Services AG68
进行中（未招募）
不适用
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionEUCTR2006-005473-21-DEovartis Pharma Services AG68
进行中（未招募）
1 期
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.MedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionHypertensionEUCTR2006-005473-21-FRovartis Pharma Services AG66
进行中（未招募）
1 期
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionEUCTR2006-005473-21-GBovartis Pharma Services AG66